Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1994-09-22
2003-08-05
Ulm, John (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C536S023500
Reexamination Certificate
active
06602983
ABSTRACT:
BACKGROUND OF THE INVENTION
The receptor with high affinity for IgE (FcERI) is found exclusively on mast cells, basophils and related cells. Aggregation of IgE occupied FcERI by antigen triggers both the release of preformed mediators such as histamine and serotonin, as well as stimulating the synthesis of leukotrienes. It is the release of these mediators which result in the allergic condition. The most thoroughly characterized FcERI is that of the rat basophilic leukemia (RBL) cell line. It consists of three different subunits: (1) A 40-50 Kilodalton (Kd) glycoprotein alpha chain which contains the binding site for IgE, (2) A single 33 Kd beta chain and (3) Two 7-9 Kd disulfide linked gamma chains. The gene for human FcERI--has never been completely cloned and isolated. Only the gene coding for the alpha subunit of tat FcERI has been cloned and sequenced [see Kinet, et al.,
Biochemistry,
26:4605 (1987)]. The instant invention encompasses the cloning, sequencing and expression of the alpha subunit of the human FcERI.
SUMMARY OF THE INVENTION
The instant invention comprises a DNA sequence coding for the polypeptide corresponding to the alpha subunit of the human high affinity receptor for IgE (human FcERI).
The instant invention also comprises a polypeptide corresponding to the alpha subunit of human FcERI.
The instant invention also includes replicable prokaryotic or eukaryotic microbial expression vehicles capable of expressing the alpha subunit of the human FcERI polypeptide, transformed prokaryotic and eukaryotic microorganisms and cultures of these microorganisms which produce the alpha subunit of human FcERI polypeptide, as well as processes for producing the alpha subunit of the human FcERI polypeptide either through solid phase synthesis methods, or through the use of recombinant DNA technology in which the requisite gene sequences are inserted by means of a suitable DNA vector into a compatible prokaryotic or eukaryotic organism.
REFERENCES:
patent: 3886132 (1975-05-01), Brewer et al.
patent: 4962035 (1990-10-01), Leder et al.
Mol. Immun. 19:1561-1567, Dec. 1982, Kumar et al. Gel Filtration in GM Guanidine Hydrochloride of the &agr;-Subunit (and its Fragments) of the Receptor for Immunosolvent.*
Conrad, et al. The Journal of Immunology, vol. 130, No. 1, pp. 327-333, (1983).
Lichtenstein, et al. Int. Archs Allergy Appl. Immun. vol. 56, pp. 473-478 (1978).
Kishi, Leukemia Research 9: 381-390 (1985).
Fischkoff, et al, Leukemia Research 11: 1105-1113 (1987).
Kinet, et al, Biochemistry, vol. 26, pp. 4605-4610 (1987).
Kinet Jean Pierre
Kochan Jarema Peter
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
Ulm John
LandOfFree
Polypeptide and DNA sequence corresponding to human receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide and DNA sequence corresponding to human receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide and DNA sequence corresponding to human receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3119957